Abstract
Current approaches for the treatment of tumours typically employ broad acting radiotherapeutic and chemotherapeutic approaches, which have led to high success rates but can be associated with unwanted side-effects. Cytotoxic T cell (CTL)-based immunotherapy offers an alternative approach that is designed to specifically target protein antigens expressed in malignant cells and is thus likely to limit any adverse side-effects. Defining tumour-specific antigens is therefore critical for the successful application of CTL-based therapy. Epstein-Barr virus (EBV)-associated malignancies offer an attractive target for CTL-based immunotherapy due to presence of virally encoded antigens in the malignant cells. Recent success in treating Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) using cytotoxic T cell (CTL)-based immunotherapy has led to interest in the development of CTL-based immunotherapy to treat other EBV-associated malignancies in which antigen expression patterns are well defined but limited to a restricted number of proteins.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Khanna, R., Moss, D., Gandhi, M. (2005) Technology insight: applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nat Clin Pract Oncol 2, 138–149.
Rooney, C. M., Smith, C. A., Ng, C. Y., et al. (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345, 9–13.
Khanna, R., Bell, S., Sherritt, M., et al. (1999) Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 96, 10391–10396.
Comoli, P., Pedrazzoli, P., Maccario, R., et al. (2005) Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 23, 8942–8949.
Straathof, K. C., Bollard, C. M., Popat, U., et al. (2005) Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood 105, 1898–1904.
Smith, C., Cooper, L., Burgess, M., et al. (2006) Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. J Immunol 177, 4897–4906.
Hislop, A. D., Taylor, G. S., Sauce, D., Rickinson, A. B. (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25, 587–617.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Smith, C., Khanna, R. (2010). Generation of Cytotoxic T Lymphocytes for Immunotherapy of EBV-Associated Malignancies. In: Yotnda, P. (eds) Immunotherapy of Cancer. Methods in Molecular Biology, vol 651. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-786-0_3
Download citation
DOI: https://doi.org/10.1007/978-1-60761-786-0_3
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-785-3
Online ISBN: 978-1-60761-786-0
eBook Packages: Springer Protocols